Saint Louis University Menu Search

Hematology, Oncology and Cellular Therapy Clinical Trials

SLUCare specialists in hematology, oncology and cellular therapy are committed to leadership in clinical research programs. As the faculty of Saint Louis University School of Medicine, our staff regularly conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.

Non-Hodgkin’s Lymphoma Study for Patients Who Were Previously Treated

SLUCare Hematology, Oncology and Cellular Therapy is seeking participants with previously treated non-Hodgkin’s lymphoma. This study is currently enrolling patients with follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma. The drugs being investigated are Ublituximab and Umbralisib, both investigational agents not yet approved by the FDA for treatment of non-Hodgkin’s lymphoma. If you think you may qualify for this study or would like more information, please contact the clinical trials team at 314-268-7061 or email: debra.king@health.slu.edu or elizabeth.ley@health.slu.edu.

View Full Study Description

Diffuse Large B-Cell Lymphoma (DLBCL) Study for Newly Diagnosed Patients     

SLUCare Hematology, Oncology and Cellular Therapy is seeking participants with newly diagnosed DLBCL. This study includes two investigational groups. One group will receive R-CHOP, an FDA-approved treatment for DLBCL, alone, while the other group will receive R-CHOP plus the study drug. If you think you may qualify for this study or would like more information, please contact the clinical trials team at 314-268-7061 or email: debra.king@health.slu.edu or elizabeth.ley@health.slu.edu.

View Full Study Description

Acute Myeloid Leukemia (AML) Study for Newly Diagnosed Patients

SLUCare Hematology, Oncology and Cellular Therapy is seeking participants who have newly diagnosed AML who have not yet received treatment. This is a study for patients with the FLT3 mutation who are not eligible for intensive induction therapy. There are three study groups. One group will receive the study drug plus Azacitidine (Vidaza), a drug approved by the FDA for treatment of patients with AML, another group will receive only Azacitidine (Vidaza), and the third group will receive only the study drug. If you think you may qualify for this study, or would like more information, please contact the clinical trials team at 314-268-7061 or email: debra.king@health.slu.edu or elizabeth.ley@health.slu.edu.

View Full Study Description